This trial will test whether the investigational agent inebilizumab is better than placebo at treating NMDAR encephalitis.
2 Primary · 6 Secondary · Reporting Duration: 96 weeks
Active Control
Non-Treatment Group
116 Total Participants · 2 Treatment Groups
Primary Treatment: Inebilizumab · Has Placebo Group · Phase 2
Age 18+ · All Participants · 10 Total Inclusion Criteria
Mark “Yes” if the following statements are true for you: